Home
Innovative Cellular Therapeutics

Innovative Cellular Ther... Market Share Analysis for May 2026

Join ICT's dynamic global team.

Industry: N/A

Domainictbio.com

Year Founded--

Employees51 - 200

Annual Revenue$5M - $10M

Innovative Cellular Therapeutics

Innovative Cellular Therapeutics (including company regionals)

ictbio.com

See more website traffic and engagement information

Innovative Cellular Therapeutics Revenue up to May 2026 is 5M - 10M

revenue generated by Innovative Cellular Therapeutics top domains

Innovative Cellular Therapeutics top domains revenue over 3 years

Revenue for Innovative Cellular Therapeutics top domains

ictbio.com5M - 10M

See more with Sales Intelligence

Total visits to Innovative Cellular Therapeutics's top domains

Understand Innovative Cellular Therapeutics market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

ictbio.com1.5K

See more with Sales Intelligence

Avg. visit duration in Innovative Cellular Therapeutics's top domains

Analyze Innovative Cellular Therapeutics engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

ictbio.com00:00:48

See more with Sales Intelligence

Avg. pageviews on Innovative Cellular Therapeutics's top domains

See how Innovative Cellular Therapeutics keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

ictbio.com1.98

See more with Sales Intelligence

Innovative Cellular Therapeutics top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by Innovative Cellular Therapeutics

These are the website technologies, by industry, used by Innovative Cellular Therapeutics top domains

Widget (8)

Twemoji

Mobile (2)

Meta Viewport

Advertising (1)

PubMatic

Content Management System (1)

WordPress

More Technologies

3

See all

News & Signals from Innovative Cellular Therapeutics

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsInnovative Cellular Therapeutics Co. sells assets to Lyell Immunopharma, Inc..Lyell Immunopharma has acquired exclusive worldwide rights from Innovative Cellular Therapeutics (ICT) to LYL273, an advanced chimeric antigen receptor (CAR) T-cell candidate for metastatic colorectal cancer and other guanylyl cyclase-C (GCC)-expressing cancers.

NewsInnovative Cellular Therapeutics Co. hired Lu as Chief Operations Officer on Apr 1st '22.Since April of 2022, Dr. Lu has served as Chief Operating Officer of Innovative Cellular Therapeutics, a clinical-stage biotechnology company focused on the development of cellular immunotherapies for the treatment of solid tumors.

NewsInnovative Cellular Therapeutics Co. hired Robert Dallimore as SVP of Quality & Compliance on Apr 6th '22.Innovative Cellular Therapeutics (ICT), a clinical stage biotechnology company developing a comprehensive platform of chimeric antigen receptor (CAR) T cell therapies with a focus on solid tumors, today announced the appointment of Robert Dallimore as SVP of Quality & Compliance.